

Vladimir J N Bykov

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5841274/publications.pdf>

Version: 2024-02-01

25
papers

4,112
citations

394421

19
h-index

642732

23
g-index

26
all docs

26
docs citations

26
times ranked

4136
citing authors

#	ARTICLE	IF	CITATIONS
1	Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound. <i>Nature Medicine</i> , 2002, 8, 282-288.	30.7	981
2	Targeting mutant p53 for efficient cancer therapy. <i>Nature Reviews Cancer</i> , 2018, 18, 89-102.	28.4	655
3	PRIMA-1 Reactivates Mutant p53 by Covalent Binding to the Core Domain. <i>Cancer Cell</i> , 2009, 15, 376-388.	16.8	508
4	Targeting p53 in Vivo: A First-in-Human Study With p53-Targeting Compound APR-246 in Refractory Hematologic Malignancies and Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2012, 30, 3633-3639.	1.6	346
5	PRIMA-1MET synergizes with cisplatin to induce tumor cell apoptosis. <i>Oncogene</i> , 2005, 24, 3484-3491.	5.9	216
6	Reactivation of Mutant p53 and Induction of Apoptosis in Human Tumor Cells by Maleimide Analogs. <i>Journal of Biological Chemistry</i> , 2005, 280, 30384-30391.	3.4	207
7	APR-246 reactivates mutant p53 by targeting cysteines 124 and 277. <i>Cell Death and Disease</i> , 2018, 9, 439.	6.3	182
8	Characterization of the p53-rescue drug CP-31398 in vitro and in living cells. <i>Oncogene</i> , 2002, 21, 2119-2129.	5.9	173
9	Mutant p53 reactivation by small molecules makes its way to the clinic. <i>FEBS Letters</i> , 2014, 588, 2622-2627.	2.8	154
10	Mutant p53-dependent growth suppression distinguishes PRIMA-1 from known anticancer drugs: a statistical analysis of information in the National Cancer Institute database. <i>Carcinogenesis</i> , 2002, 23, 2011-2018.	2.8	152
11	Targeting of Mutant p53 and the Cellular Redox Balance by APR-246 as a Strategy for Efficient Cancer Therapy. <i>Frontiers in Oncology</i> , 2016, 6, 21.	2.8	99
12	Mutant p53 targeting by the low molecular weight compound STIMA-1. <i>Molecular Oncology</i> , 2008, 2, 70-80.	4.6	91
13	p53 as a hub in cellular redox regulation and therapeutic target in cancer. <i>Journal of Molecular Cell Biology</i> , 2019, 11, 330-341.	3.3	71
14	Inhibition of the glutaredoxin and thioredoxin systems and ribonucleotide reductase by mutant p53-targeting compound APR-246. <i>Scientific Reports</i> , 2018, 8, 12671.	3.3	53
15	Novel cancer therapy by reactivation of the p53 apoptosis pathway. <i>Annals of Medicine</i> , 2003, 35, 458-465.	3.8	52
16	Mutant p53 rescue and modulation of p53 redox state. <i>Cell Cycle</i> , 2009, 8, 2509-2517.	2.6	43
17	A thiol-bound drug reservoir enhances APR-246-induced mutant p53 tumor cell death. <i>EMBO Molecular Medicine</i> , 2021, 13, e10852.	6.9	28
18	The Mutant p53-Targeting Compound APR-246 Induces ROS-Modulating Genes in Breast Cancer Cells. <i>Translational Oncology</i> , 2018, 11, 1343-1349.	3.7	25

#	ARTICLE	IF	CITATIONS
19	Synergistic Rescue of Nonsense Mutant Tumor Suppressor p53 by Combination Treatment with Aminoglycosides and Mdm2 Inhibitors. <i>Frontiers in Oncology</i> , 2017, 7, 323.	2.8	22
20	Role of Thiol Reactivity for Targeting Mutant p53. <i>Cell Chemical Biology</i> , 2018, 25, 1219-1230.e3.	5.2	20
21	Needling With 5-Fluorouracil (5-FU) After XEN Gel Stent Implantation: 6-Month Outcomes. <i>Journal of Glaucoma</i> , 2018, 27, 893-899.	1.6	18
22	Mutant p53-reactivating compound APR-246 synergizes with asparaginase in inducing growth suppression in acute lymphoblastic leukemia cells. <i>Cell Death and Disease</i> , 2021, 12, 709.	6.3	11
23	Mutant p53 Reactivation as a Novel Strategy for Cancer Therapy. , 2007, , 399-419.		1
24	Cancer Therapy by Reactivation of the p53 Apoptosis Pathway. , 0, , 891-912.		0
25	Targeting Mutant p53 for Improved Cancer Therapy. , 2013, , 257-273.		0